Trellis Bioscience
PrivateLast Round
Series C
Jul 16, 2026
Total Funding Raised
$26.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Trellis Bioscience is a biotechnology company that develops native human monoclonal antibody therapies for infectious diseases and cancer using its proprietary CellSpot™ discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Trellis Bioscience Comparables
Compare Trellis Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Peptilogics | 81% | |
| Aridis Pharmaceuticals, Inc. | 79% | |
| Clarametyx Biosciences | 79% |
Trellis Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 16, 2026 | ||||
| Series C | May 15, 2026 | ||||
| VC Round | Oct 22, 2024 | ||||
| Grant | Jul 18, 2024 | ||||
| Grant | Jan 14, 2020 | ||||
Grant | Aug 16, 2012 |
Key People
Founding team and executive leadership
Trellis Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pac-Link Bio Venture Investment Corporation | Series B |
| AMR Action Fund | Series C |
| National Institute of Allergy and Infectious Diseases | Grant |
| CARB-X | Grant |
| Sagamore Bioventures LLC | Series B |
| Easton-Hunt Capital Partners, L.P. | Series B, Series C |
| Nodenza Venture Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 72% MoM.
- Jul 16, 2026
$9M round led by Easton-Hunt Capital Partners.
Recent news
Latest coverage and updates
- hiresJul 16, 2026
Trellis Bioscience, Inc. hired Junjun Gao as Board of Directors on Jul 16th '26.
- receives_financingJul 16, 2026
Trellis Bioscience, Inc. received financing of $9M in Series C on Jul 16th '26.
Trellis Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Trellis Bioscience's valuation, stock price, and market status.
Is Trellis Bioscience a public or private company?
Trellis Bioscience is a private company.
What is the current stock price of Trellis Bioscience?
Trellis Bioscience is a private company with no public stock price. No recent secondary market data is available.
How much is Trellis Bioscience worth (valuation)?
Valuation information for Trellis Bioscience is not publicly available.
Can I buy Trellis Bioscience stock?
Trellis Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Trellis Bioscience's last funding round?
Trellis Bioscience's most recent funding round was Series C on May 15, 2026.
Who are the main investors in Trellis Bioscience?
Key investors in Trellis Bioscience include National Institute of Allergy and Infectious Diseases, CARB-X, Nodenza Venture Partners.
Will Trellis Bioscience IPO soon?
No public IPO plans have been announced for Trellis Bioscience.
How can I track Trellis Bioscience secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Trellis Bioscience's secondary market activity and sign up for updates.